Results 21 to 30 of about 19,188,680 (306)

Mycophenolate mofetil as second line treatment in autoimmune hepatitis – A retrospective single center analysis [PDF]

, 2022
Background: Most patients with autoimmune hepatitis respond to standard treatment with steroids and azathioprine. While the disease is usually fatal if untreated, patients who respond well to therapy have an excellent prognosis. Nevertheless, second-line
Annalisa Berzigotti, Nasser Semmo, Rodrigues, Susana G., Susana G. Rodrigues, Stefan Diem, Diem, Lara, Kolev, Mirjam, G. Rodrigues, Susana, Berzigotti, Annalisa, Guido Stirnimann, Semmo, Nasser, Mirjam Kolev, Stirnimann, Guido, Diem, Stefan, Lara Diem   +14 more
core   +2 more sources

Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia [PDF]

, 2007
Background: Irinotecan-based second-line chemotherapy of metastatic colorectal cancer (CRC) is effective, it might, however, be contraindicated in cases of severe liver dysfunction due to advanced liver metastases.
Moosmann, Nicolas, Schulz, Christoph, Laessig, Dorit, Michaely, Henrik Jakob, Heinemann, Volker   +4 more
core   +1 more source

First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort

, 2022
Background: Metastatic pancreatic ductal adenocarcinoma (PDAC) is characterized by a poor survival rate, which can be improved by systemic treatment. Consensus on the most optimal first- and second-line palliative systemic treatment is lacking.
Creemers, G.J., Creemers, Geert-Jan, Besselink, M.G., Besselink, Marc G., Wilmink, Johanna W., Mohammad, N.H., Dijksterhuis, Willemieke P.M., Dijksterhuis, W.P.M., Wilmink, J.W., Creemers, Geert Jan, Dijksterhuis, Willemieke P. M., van Laarhoven, Hanneke W. M., Pijnappel, E.N., de Vos-Geelen, J., van Laarhoven, Hanneke W.M., Homs, Marjolein Y. V., de Vos-Geelen, Judith, de Groot, J.W.B., de Groot, Jan Willem B., van der Geest, Lydia G., Mohammad, Nadia Haj, van der Geest, L.G., van Laarhoven, H.W.M., Homs, Marjolein Y.V., Homs, M.Y.V., Pijnappel, Esther N.   +25 more
core   +1 more source

European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain

Antibiotics, 2020
The management of Helicobacter pylori infection has to rely on previous local effectiveness due to the geographical variability of antibiotic resistance. The aim of this study was to evaluate the effectiveness of first and second-line H. pylori treatment
María Caldas, Ángeles Pérez-Aisa, Manuel Castro-Fernández, Luis Bujanda, Alfredo J. Lucendo, Luis Rodrigo, Jose M. Huguet, Jorge Pérez-Lasala, Javier Molina-Infante, Jesús Barrio, Luis Fernández-Salazar, Ángel Lanas, Mónica Perona, Manuel Domínguez-Cajal, Juan Ortuño, Blas José Gómez-Rodríguez, Pedro Almela, Josep María Botargués, Óscar Núñez, Inés Modolell, Judith Gómez, Rafael Ruiz-Zorrilla, Cristóbal De la Coba, Alain Huerta, Eduardo Iyo, Liliana Pozzati, Rosario Antón, Mercé Barenys, Teresa Angueira, Miguel Fernández-Bermejo, Ana Campillo, Javier Alcedo, Ramón Pajares-Villaroya, Marianela Mego, Fernando Bermejo, José Luis Dominguez-Jiménez, Llúcia Titó, Nuria Fernández, Manuel Pabón-Carrasco, Ángel Cosme, Pilar Mata-Romero, Noelia Alcaide, Inés Ariño, Tommaso Di Maira, Ana Garre, Ignasi Puig, Olga P. Nyssen, Francis Megraud, Colm O’Morain, Javier P. Gisbert   +49 more
doaj   +1 more source

Lenvatinib as second-line treatment in patients with unresectable hepatocellular carcinoma: A retrospective analysis

Frontiers in Oncology, 2022
ObjectiveThe purpose of this study is to determine the efficacy and safety of lenvatinib as second-line therapy in Chinese patients with unresectable hepatocellular carcinoma (HCC).MethodsWe performed a retrospective analysis of Chinese patients with ...
He-nan Qin, Zhen Ning, Rui Sun, Chen-xing Jin, Xin Guo, A-man Wang, Ji-wei Liu   +6 more
doaj   +1 more source

REAL-LIFE CLINICAL UTILITY OF RAMUCIRUMAB FOR THE TREATMENT OF PATIENTS WITH DISSEMINATED GASTRIC ADENOCARCINOMA: PRELIMINARY REVIEW OF THE EXPERIENCE OF BLOKHIN RUSSIAN CANCER RESEARCH CENTRE

Медицинский совет, 2017
Angiogenesis   has  become  an  important  target  in  the  treatment  of  solid  tumors  and  anti-angiogenic   agents   are a  promising  approach  to  cancer  therapy.
N. S. Besova, T. A. Titova, V. A. Gorbunova, O. O. Gordeeva, A. A. Tryakin, A. V. Snegovoy, R. Yu. Nasyrova, A. A. Rumyantsev, E. A. Voroshilova, E. V. Artamonova   +9 more
doaj   +1 more source

Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda. [PDF]

, 2014
We investigated phenotypic and genotypic resistance after 2 years of first-line therapy with two HIV treatment regimens in the absence of virological ...
Awio, P., Munderi, P., Pillay, D., Ndembi, N., Nkurunziza, P., Ndembi, N, Pattery, T, Dunn, DT, van Cauwenberge, A, Gilks, C. F., Gilks, CF, Awio, P, Munderi, P, Nkurunziza, P, Kaleebu, P., Pillay, D, Goodall, RL, DART Virology Group and Trial Teams, Kaleebu, P, Goodall, R. L., Kityo, C., Dunn, D. T., Kityo, C, Pattery, T., van Cauwenberge, A., K. Mataruka, B. Kikaire, M. Nabankkema, H. Grosskurth, P. Khauka, M. Namyalo, C. Kityo, C. Parry, C. F. Gilks, M. Spyer, R. Magala, P. Kaleebu, R. L. Goodall, P. Nkurunziza, N. Ndembi, R. Goodall, A. Zalwango, T. Pattery, L. Generous, P. Awio, D. Dunn, D. Pillay, K. Fadhiru, G. Kabuye, L. Mugarura, G. Nassuna, M. Chirara, M. Katuramur, B. Magambo, J. Nkalubo, R. Massa, A. van Cauwenberge, E. Zalwango, V. Robertson, P. Munderi, D. Yirrell, R. Kasirye, D. M. Gibb, A. Kapaata, D. T. Dunn, D. Nsibambi, F. Lyagoba, T. Musunga, A.L. McCormick, M. Nakazibwe, C. Gilks   +70 more
core   +1 more source

Clinical example of enhancing efficacy of paclitaxel by combining it with ramuchirumabin in the second-line chemotherapy of disseminated gastric cancer

Медицинский совет, 2019
The low efficacy of cytostatic therapy in mGC led to an active study of the role of molecular targets in the carcinogenesis of GC. Ramucirumab is the only neoangiogenesis inhibitor, which demonstrated its antitumor activity both as monotherapy and in ...
T. A. Titova, E. V. Artamonova, N. S. Besova   +2 more
doaj   +1 more source

Pre-extensively drug-resistant tuberculosis spondylodiscitis in an immunocompetent patient: a case report

The Pan African Medical Journal, 2020
Pre-extensively drug resistant tuberculosis (pre-XDR-TB) has been an area of growing concern, and posing a threat to global efforts of TB control. We report a case of PreXDR-TB spondylodiscitis with resistance to a Fluoroquinolone, in an immunocompetent ...
Safaa Fellous, Hanan Rkain, Latifa Tahiri, Amina Bouraqadi, Ittimad Nassar, Fadoua Allali   +5 more
doaj   +1 more source

Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients

BMC Cancer, 2021
Background Limited treatment options exist for relapsed advanced lung squamous cell carcinoma (SCC), leading to poor outcomes compared with adenocarcinoma.
You-Yi Chen, Shih-Chieh Chang, Cheng-Yu Chang, Chun-Fu Chang, Yi-Chun Lai, Yu-Feng Wei, Chung-Yu Chen   +6 more
doaj   +1 more source